Suzhou Biosynthetica Co., Ltd.

Suzhou Biosynthetica Co. , Ltd. is a Chinese company focused on the innovative development of nucleotide-related raw materials and active pharmaceutical ingredients using synthetic biology techniques. Founded in 2014, Suzhou Biosynthetica Co.

, Ltd. operates out of Suzhou, China, specializing in synthetic biology to produce essential compounds for pharmaceuticals and nutritional products. The company has successfully raised CNY 100 million in Series A funding led by Hunan Xingxiang Investment Holding Group, with participation from Zero2IPO Ventures and Zhangjiagang Industrial Capital Center. The total amount raised to date is CNY 100 million from one deal, with the most recent funding round occurring on January 2, 2026.

Suzhou Biosynthetica Co. , Ltd. specializes in the development and production of nucleotide-related raw materials and active pharmaceutical ingredients (APIs) through innovative synthetic biology techniques. The company focuses on creating novel microorganisms that efficiently produce key compounds such as nucleotides, which are essential in pharmaceuticals, nutritional supplements, and various food products.

Their offerings include L-Histidine, L-Carnosine, and other amino acid derivatives, which are utilized in health products, flavoring agents, and feed additives. The firm serves a diverse clientele, including pharmaceutical companies, nutritional supplement manufacturers, and food industry players, primarily in Asian markets, while also targeting expansion into North America and Europe. By leveraging metabolic engineering, the company aims to enhance production efficiency and reduce costs associated with API manufacturing, addressing the growing demand for sustainable and high-quality ingredients. Suzhou Biosynthetica's revenue model is primarily based on B2B transactions, facilitating partnerships with various companies in the pharmaceutical and nutritional sectors.

The company engages in direct sales of its products, including flagship offerings like L-Histidine and other specialized amino acids, to its commercial clients. The transaction structure typically involves bulk orders and long-term supply agreements, allowing businesses to integrate these ingredients into their own product lines. Pricing is determined according to the specific needs of clients and the scale of production, accommodating both small-scale and large-scale operations. This transactional framework fosters ongoing relationships with clients and positions the company as a reliable supplier of high-quality bioproducts in a competitive market.

In January 2026, Suzhou Biosynthetica Co. , Ltd. raised approximately CNY 100 million in Series A funding, which will be primarily utilized for the construction and implementation of green production capacity. The company plans to expand its product offerings and aims to penetrate new markets, specifically targeting North America and Europe for growth by 2028.

This funding will support the development of new products and enhance their production capabilities to meet increasing market demand.